Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin® Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

NCT02272413 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02272413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02272413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin® Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2015
Completion date
November 16, 2018
Enrollment
671 (actual)
Sites
189

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung